Contact Information

Title
Assistant Professor
Office
(Office) E12-3022
/ (Lab) N22-3013
Phone
(Office) +853 8822 4824
/ (Lab) +853 8822 2953
Fax
+853 8822 2314
Email
Consultation Hours
Tue, Fri 10:00 – 11:00
Teaching
Research Team
Name | Position | Office | Phone | |
---|---|---|---|---|
Lianwei FENG | Research Assistant | N22-3013 | +853 8822 2953 | lianweifeng@um.edu.mo |
Zihan ZHAO | PhD Student | N22-3013 | +853 8822 2953 | |
Zhizhen CHEN | PhD Student | N22-3013 | +853 8822 2953 | |
Guanyu ZHOU | PhD Student | N22-3013 | +853 8822 2953 | |
Shigao HUANG | PhD Student | N22-3013 | +853 8822 2953 | |
Lipeng ZHU | PhD Student | N22-3013 | +853 8822 2953 | |
Yingjun PENG | PhD Student | N22-2013 | +853 8822 2953 | |
Shengyu FU | PhD Student | N22-3013 | +853 8822 2953 | |
Fengjuan ZHANG | PhD Student | N22-3013 | +853 8822 2953 | |
Jiaqi WANG | PhD Student | N22-3013 | +853 8822 2953 | |
Ziang GUO | PhD Student | N22-3013 | +853 8822 2953 | |
Ziyi YANG | PhD Student | N22-3013 | +853 8822 2953 | |
Yue WANG | PhD Student | N22-3013 | +853 8822 2953 |
Education | |
PhD | Department of Biochemistry, The Chinese University of Hong Kong |
MSc | College of Life Sciences, Jilin University |
BSc | College of Life Sciences, Jilin University |
Position | |
2016-present | Assistant Professor, Faculty of Health Sciences, University of Macau |
2013-2016 | Principle Investigator, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences |
2011-2013 | Research Associate, Memorial Sloan-Kettering Cancer Center |
2008-2011 | Postdoctoral Fellow, National Cancer Institute, NIH |
Research Interests |
Our group is interested in the development of antibody-based therapeutics for cancer. The research focuses on engineering of monoclonal antibodies, bispecific antibodies, or chimeric antigen receptors (CARs), the delivery of drugs via the nanoparticles. We are identifying novel human monoclonal antibodies from antibody phage libraries. Monoclonal antibodies are designed to destroy tumor cells by utilizing mechanisms of antibody-dependent cellular cytotoxicity (ADCC) or antibody-drug conjugation (ADC). By using these antibodies as vehicles, bispecific antibodies directed at tumor antigens and human CD3 can engage T cells to lyse tumors. Additionally, all of these antibodies can be reshaped to build CAR to redirect T cells. Meanwhile, based on various antibody and immune cell formats, nanoparticle drug delivery systems are built for the targeted delivery and controlled release of therapeutic agents.
Areas of Expertise: (1) Antibody-based therapeutics; (2) Immune cell therapy; (3) Antibody display systems; (4) Nanomedicine |
Representative Publications |
|
Full Publications List |
Research Grants |
|
Patents |
|
Awards |
Federal Technology Transfer Award, NIH, USA, 2011 |
Others |
Conference Presentations
Teaching of undergraduate students
|